The neuroblastoma drugs market will register a CAGR of over 4% by 2023

Thursday, March 28, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, March 27, 2019 /PRNewswire/ -- About this marketNeuroblastoma is the most common type of childhood cancer.

and its incidence is gradually increasing across the world. The exact etiological factor contributing to neuroblastoma remains undefined. However, the rising birth rate is a major contributor to the growing incidence of neuroblastoma. The incidence of
neuroblastoma is increasing in developed as well as developing countries. Thus, the rising incidence of neuroblastoma is one of the driving factors for the market growth. Technavio's analysts have predicted that the neuroblastoma drugs market will register a CAGR of over 4% by 2023.Download the full report: https://www.reportbuyer.com/product/5734217/?utm_source=PRN Market OverviewGrowing demand for anti-GD2 antibodiesThe identification of the therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth is a promising field in cancer research. GD2 (O-acetyl-GD2 ganglioside) has been identified as a cell surface antigen that is overexpressed in neuroblastoma. These drugs do not pose any cytotoxic effects in the body. Therefore, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma.High cost of treatmentChildren with neuroblastoma typically undergo many rounds of complex and intensive treatment, comprising several cycles of chemotherapy. The long duration increases the treatment costs. Drugs for the treatment of neuroblastoma, especially immunotherapy drugs, are considerably expensive. This increases the manufacturing costs of these drugs and subsequently the prices.For the detailed list of factors that will drive and challenge the growth of the neuroblastoma drugs market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be moderately concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Download the full report: https://www.reportbuyer.com/product/5734217/?utm_source=PRN About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-neuroblastoma-drugs-market-will-register-a-cagr-of-over-4-by-2023-300819460.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store